Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Source: 
Fierce Pharma
snippet: 

Novartis and Eli Lilly have been jockeying for new indications and commercial success for their IL-17 inhibitors Cosentyx and Taltz, respectively. Lilly appeared to get the label-expansion edge with the FDA's blessing for a fourth indication earlier this month, but Novartis was hot on its rival's heels—and now has a Cosentyx approval to match.